Compare Adaptive Biotechnologies Corp (ADPT) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.87 (market cap $3.33B), while T-Rex 2X Long MSTR Daily Target ETF trades at $1.87. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | MSTU | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $22.37 | $106.80 |
52-Week Low | $10.24 | $1.46 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
MSTU trades at $2.15, unchanged on the day, with a bearish technical outlook indicated by moving averages and ADX signals. The ETF has experienced extreme volatility, with news reports highlighting a 95% annual decline. Key support and resistance are at $2 and $3, respectively. Financial ratios are unavailable, and the fund's performance is directly tied to the daily moves of its underlying asset.
The outlook for MSTU is highly speculative and carries significant risk due to its leveraged structure, which can amplify losses. Investor sentiment is negative following substantial historical declines. Any investment is a high-risk bet on short-term price movements of the underlying asset, not a long-term fundamental holding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →
